GU Oncology

Expert-driven insights across genitourinary cancers, including bladder, kidney, and prostate malignancies, with a focus on evolving systemic therapies and multidisciplinary care. Highlights treatment sequencing, biomarker integration, and emerging clinical data to support evidence-based decision-making.

BLADDER CANCER

Browse all BLADDER CANCER

BLADDER CANCER

Ep. 4: Multidisciplinary Approaches to Emerging Bladder Cancer Treatments

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Sia Daneshmand, MD, Chad Reichard, MD, Shilpa Gupta, MD

BLADDER CANCER

Ep. 3: Optimizing Perioperative ADC and Immunotherapy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Sia Daneshmand, MD, Chad Reichard, MD, Shilpa Gupta, MD

BLADDER CANCER

Ep. 2: Coordinating Systemic Therapy and Radical Cystectomy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Sia Daneshmand, MD, Chad Reichard, MD, Shilpa Gupta, MD

BLADDER CANCER

Ep. 1: NIAGARA: Shifting the Treatment Landscape in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Matt Galsky, MD, Shilpa Gupta, MD, Sia Daneshmand, MD, Chad Reichard, MD

RCC

Browse all RCC

RCC

Ep. 5: Optimizing Sequential Therapy in Advanced RCC

Bradley McGregor, MD, Ulka Vaishampayan, MBBS, David Braun, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

RCC

Ep. 4: Second-Line RCC Management: Tolerability, Comorbidities, and Long-Term Planning

Ulka Vaishampayan, MBBS, Bradley McGregor, MD, David Braun, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

RCC

Ep. 3: Balancing Patient Goals and Efficacy in Second-Line RCC Therapy

David Braun, MD, PhD, Ulka Vaishampayan, MBBS, Bradley McGregor, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

RCC

Ep. 2: VEGF TKIs in RCC: Toxicity and Tolerability

David Braun, MD, PhD, Bradley McGregor, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD